Great Point Partners (GPP) announced on June 13 the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization (CDMO) based in Ilsenburg, Germany.
Founded in 2007, Lyocontract operates from a state-of-the-art pharmaceutical manufacturing facility providing aseptic liquid filling, lyophilization and packaging services. Compliant with the European Union’s Annex 1 standards, the CDMO specializes in the production of liquid and freeze-dried parenteral drugs, distributing globally for both clinical and commercial use.
Founded in 2003 and based in Greenwich, Connecticut, GPP is a healthcare investment firm that has provided growth equity, growth recapitalization and management buyout financing to more than 200 healthcare companies in the United States, Canada and western Europe. GPP is making new private equity investments from GPP IV, which focuses on the lower middle market healthcare sector.
The acquisition marks the first investment to be sourced and executed by GPP’s European team, which is based in the firm’s recently opened London office. The transaction will expand Lyocontract’s global footprint and diversify its service offerings. Rantum Capital provided debt financing for this acquisition. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 15th CDMO deal of 2024. Of those 15 deals, 60% (10 transactions) of CDMO targets have been acquired by private equity firms and/or their portfolio companies. There were 21 CDMO transactions announced during 2023, and 38 announced during 2022.
